Zura Bio Limited
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | +200.0% | +66.7% | +80.0% | +22.2% | +27.3% | +7.1% | +6.7% | +0.0% | – | |
| – | -7.1% | +0.6% | +21.5% | +195.5% | -67.4% | +29.4% | +2.4% | -36.3% | +8.3% | +94.3% | -11.0% | – | |
| – | +6.2% | -107.5% | – | +13,268.4% | -101.0% | – | -241.5% | – | -1,475.6% | – | +1,242.1% | – | |
| – | -100.0% | – | -99.8% | +30.0% | +246.2% | +8.9% | -69.4% | +113.3% | -46.9% | -23.5% | +84.6% | – | |
| – | – | – | -99.8% | +30.0% | +246.2% | +8.9% | -69.4% | +113.3% | -46.9% | -23.5% | +84.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -100.0% | – | – | -94.8% | -115.7% | – | -100.7% | – | -243,933.3% | – | -99.7% | – | |
| – | – | – | – | -100.2% | – | – | – | – | – | – | -117.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.